Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ranitidine hydrochloride, quantity: 168 mg (equivalent: ranitidine, qty 150 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; hypromellose; castor oil; iron oxide yellow; titanium dioxide; purified talc - indicated for short-term treatment of proven duodenal ulcer and gastric ulcer; maintenance treatment to reduce the risk of relapse in duodenal ulcer; maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer; treatment of gastrinoma (zollinger-ellison syndrome); short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids; maintenance treatment to reduce the risk of relapse of reflux oesophagitis; treatment of scleroderma oesophagitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ranitidine hydrochloride, quantity: 168 mg (equivalent: ranitidine, qty 150 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; croscarmellose sodium; titanium dioxide; macrogol 8000; hypromellose; polydextrose; triethyl citrate - short-term treatment of proven duodenal ulcer and gastric ulcer. maintenance treatment to reduce the risk of relapse in duodenal ulcer. maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. treatment of gastrinoma (zollinger-ellison syndrome). short-term symptomatic treatment of reflux oesophagitis, unresponsive to conservative antireflux measures and simple drug therapies such as antacids. maintenance treatment to reduce risk of relapse of reflux oesophagitis. treatment of scleroderma oesophagitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ranitidine hydrochloride, quantity: 168 mg (equivalent: ranitidine, qty 150 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; hypromellose; castor oil; iron oxide yellow; titanium dioxide; purified talc - indicated for short-term treatment of proven duodenal ulcer and gastric ulcer; maintenance treatment to reduce the risk of relapse in duodenal ulcer; maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer; treatment of gastrinoma (zollinger-ellison syndrome); short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids; maintenance treatment to reduce the risk of relapse of reflux oesophagitis; treatment of scleroderma oesophagitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - ranitidine hydrochloride, quantity: 168 mg (equivalent: ranitidine, qty 150 mg) - tablet, effervescent - excipient ingredients: sodium benzoate; povidone; sodium bicarbonate; monosodium dihydrogen citrate; aspartame; flavour - short term treatment of proven duodenal and gastric ulcer. maintenance treatment to reduce the risk of relapse in duodenal ulcer. maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. treatment of gastrinoma (zollinger-ellison syndrome). short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids. treatment of scleroderma oesophagitis. new indications as at 2 november 1993: 1. short-term treatment of proven duodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. maintenance treatment to reduce the risk of relapse in duodenal ulcer. 3. maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. treatment of gastrinoma (zollinger-ellison syndrome). 5. short- term symptomatic treatment of reflux oe

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ranitidine hydrochloride, quantity: 168 mg (equivalent: ranitidine, qty 150 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; croscarmellose sodium; titanium dioxide; macrogol 8000; hypromellose; polydextrose; triethyl citrate - short-term treatment of proven duodenal ulcer and gastric ulcer. maintenance treatment to reduce the risk of relapse in duodenal ulcer. maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. treatment of gastrinoma (zollinger-ellison syndrome). short-term symptomatic treatment of reflux oesophagitis, unresponsive to conservative antireflux measures and simple drug therapies such as antacids. maintenance treatment to reduce risk of relapse of reflux oesophagitis. treatment of scleroderma oesophagitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - ranitidine hydrochloride, quantity: 168 mg (equivalent: ranitidine, qty 150 mg) - tablet, effervescent - excipient ingredients: sodium bicarbonate; sodium benzoate; aspartame; monosodium dihydrogen citrate; povidone; flavour - short term treatment of proven duodenal and gastric ulcer. maintenance treatment to reduce the risk of relapse in duodenal ulcer. maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. treatment of gastrinoma (zollinger-ellison syndrome). short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids. treatment of scleroderma oesophagitis. indications as at 2 november 1993: 1. short-term treatment of proven duodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. maintenance treatment to reduce the risk of relapse in duodenal ulcer. 3. maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. treatment of gastrinoma (zollinger-ellison syndrome). 5. short-term symptomatic treatment of reflux oesopha

United States - English - NLM (National Library of Medicine)

sandoz inc - ranitidine hydrochloride (unii: bk76465ihm) (ranitidine - unii:884kt10yb7) - ranitidine 150 mg - ranitidine hydrochloride is indicated in: concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; gerd; and erosive esophagitis. ranitidine hydrochloride is contraindicated for patients known to have hypersensitivity to the drug or any of the ingredients (see precautions ).

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - ranitidine hydrochloride, quantity: 168 mg (equivalent: ranitidine, qty 150 mg) - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; triacetin - effective long lasting relief from heartburn and acid indigestion

United States - English - NLM (National Library of Medicine)

avkare, inc. - ranitidine hydrochloride (unii: bk76465ihm) (ranitidine - unii:884kt10yb7) - ranitidine 150 mg -   ranitidine is indicated in: - short-term treatment of active duodenal ulcer. most patients heal within 4 weeks. studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. no placebo-controlled comparative studies have been carried out for periods of longer than 1 year. - the treatment of pathological hypersecretory conditions (e.g., zollinger-ellison syndrome and systemic mastocytosis). - short-term treatment of active, benign gastric ulcer. most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. studies available to date have not assessed the safety of ranitidine in uncomplicated benign gastric ulcer for periods of more than 6 weeks. - maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. placebo-controlled studies have been carried out for 1 year

United States - English - NLM (National Library of Medicine)

dr. reddy's laboratories limited - ranitidine hydrochloride (unii: bk76465ihm) (ranitidine - unii:884kt10yb7) - ranitidine 150 mg -   ranitidine is indicated in:   1. short-term treatment of active duodenal ulcer. most patients heal within 4 weeks. studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. 2. maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. no placebo-controlled comparative studies have been carried out for periods of longer than 1 year. 3.the treatment of pathological hypersecretory conditions (e.g., zollinger-ellison syndrome and systemic mastocytosis). 4. short-term treatment of active, benign gastric ulcer. most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. 5.maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. placebo-controlled studi